Compare Adaptive Biotechnologies Corp (ADPT) vs Hilton Hotels Corporation Common Stock (HLT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Hilton Hotels Corporation Common Stock — how do they compare? Adaptive Biotechnologies Corp trades at $19.96 (market cap $3.33B), while Hilton Hotels Corporation Common Stock trades at $334.02 (market cap $77.66B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 23.3× Adaptive Biotechnologies Corp's market cap, and Hilton Hotels Corporation Common Stock pays a 0.18% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | HLT | |
|---|---|---|
Market Cap | $3.33B | $77.66B |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $350.22 |
52-Week Low | $10.24 | $256.75 |
Enterprise Value | $3.19B | $90.15B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Hilton Worldwide (HLT) trades at $341.12, up 0.89% with strong technical momentum as price approaches resistance at $342. The stock shows consistent earnings beats with Q1 2026 EPS of $2.01 exceeding expectations of $1.98, while revenue growth continues from $12.04B in 2025 to projected $12.3B in 2026. Analyst consensus remains bullish with 55% buy ratings and a $342.11 price target closely aligned with current levels.
The outlook remains positive given Hilton's market leadership and sustained travel demand, though elevated debt levels and valuation multiples present risks. With technical indicators showing bullish momentum and strong institutional support, the stock appears positioned for continued growth, though investors should monitor debt management and competitive pressures in the hospitality sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →
